Perjeta and Red cell distribution width increased - a phase IV clinical study of FDA data

Summary:

Red cell distribution width increased is reported as a side effect among people who take Perjeta (pertuzumab), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Taxotere, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Red cell distribution width increased when taking Perjeta. It is created by eHealthMe based on reports of 13,356 people who have side effects when taking Perjeta from the FDA, and is updated regularly.

What is Perjeta?

Perjeta has active ingredients of pertuzumab. eHealthMe is studying from 13,388 Perjeta users. Check the latest studies of Perjeta.

What is Red cell distribution width increased?

Red cell distribution width increased is found to be associated with 607 drugs and 653 conditions by eHealthMe. Check the latest studies of Red cell distribution width increased.

On Jul, 13, 2026

13,356 people reported to have side effects when taking Perjeta.
Among them, 92 people (0.69%) have Red cell distribution width increased.

Could Perjeta cause Red cell distribution width increased?

Among these 92 people:

How long have people been on Perjeta when they have Red cell distribution width increased? *

What is the gender of people who have Red cell distribution width increased when taking Perjeta? *

female: 100 %
male: 0.0 %

What is the age of people who have Red cell distribution width increased when taking Perjeta? *

What are other drugs people take besides Perjeta? *

What are other side effects people have besides Red cell distribution width increased? *

Lymphocyte Count Decreased: 78 people, 84.78%
Haematocrit Decreased: 71 people, 77.17%
Red Blood Cell Count Decreased: 70 people, 76.09%
Haemoglobin Decreased: 62 people, 67.39%
Fatigue (feeling of tiredness): 61 people, 66.30%
Thrombocytopenia (decrease of platelets in blood): 58 people, 63.04%
Weight Decreased: 58 people, 63.04%
Hypotension (abnormally low blood pressure): 52 people, 56.52%
White Blood Cell Count Decreased: 50 people, 54.35%
Blood Alkaline Phosphatase Increased: 46 people, 50.00%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 41 people, 44.57%
Breast Cancer: 25 people, 27.17%
Cough: 17 people, 18.48%
Insomnia (sleeplessness): 6 people, 6.52%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 3.26%
Metastatic Salivary Gland Cancer (salivary gland cancer spreads to other part): 2 people, 2.17%
Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 2 people, 2.17%
Cardiac Disorder: 2 people, 2.17%
Pain: 1 person, 1.09%
Diarrhea: 1 person, 1.09%

* Approximation only. Some reports may have incomplete information.

Do you take Perjeta and have Red cell distribution width increased?

- Check whether Red cell distribution width increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Perjeta:

Perjeta (13,388 reports)

Browse all side effects of Perjeta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Red cell distribution width increased:

Red cell distribution width increased (607 drugs)

Browse all the conditions that are associated with Red cell distribution width increased:

Red cell distribution width increased (653 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pertuzumab (the active ingredients of Perjeta) and Perjeta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.